Prognostic value of p16, p53, and pcna in sarcoma and an evaluation of immune infiltration
Open Access
- 10 June 2022
- journal article
- research article
- Published by Springer Nature in Journal of Orthopaedic Surgery and Research
- Vol. 17 (1) , 1-14
Abstract
P16, p53, and proliferating cell nuclear antigen (pcna) genes play significant roles in many chromatin modifications and have been found to be highly expressed in a variety of tumor tissues. Therefore, they have been used as target genes for some tumor therapies. However, the differential expressions of the p16, p53, and pcna genes in human sarcomas and their effects on prognosis have not been widely reported. The Oncomine dataset was used to analyze the transcription levels of p16, p53, and pcna genes, and the gene expression profile interactive analysis (GEPIA) dataset was used to analyze the differential expressions of p16, p53, and pcna. The expression levels of p16, p53, and pcna were further analyzed by Western Blotting. GEPIA and Kaplan–Meier analyses were used to analyze the prognostic value of p16, p53, and pcna. Furthermore, p16, p53, and pcna gene mutations and their association with overall survival (OS) and disease-free survival (DFS) were analyzed using cBioPortal datasets. In addition, genes co-expressed with p16, p53, and pcna were analyzed using Oncomine. The DAVID dataset was used to analyze the functional enrichment of p16, p53, pcna, and their co-expressed genes by Gene Ontology (GO) and Metascape were used to construct a network map. Finally, the immune cell infiltration of p16, p53, and pcna in patients with sarcoma was reported by Tumor Immune Estimation Resource (TIMER). p16, p53, and pcna were up-regulated in human sarcoma tissues and almost all sarcoma cell lines. Western Blotting showed that the expression of p16, p53, and pcna was elevated in osteosarcoma cell lines. The expression of pcna was correlated with OS, the expression of p16, p53, and pcna was correlated with relapse-free survival, and the genetic mutation of p16 was negatively correlated with OS and DFS. We also found that p16, p53, and pcna genes were positively/negatively correlated with immune cell infiltration in sarcoma. The results of this study showed that p16, p53, and pcna can significantly affect the survival and immune status of sarcoma patients. Therefore, p16, p53, and pcna could be used as potential biomarkers of prognosis and immune infiltration in human sarcoma and provide a possible therapeutic target for sarcoma.Keywords
Funding Information
- 中国安徽省科技厅 (S202007d0705001, S202007d0705001, S202007d0705001, S202007d0705001, S202007d0705001, S202007d0705001, S202007d0705001)
This publication has 85 references indexed in Scilit:
- Update on Survival in OsteosarcomaOrthopedic Clinics of North America, 2016
- Genomic Landscape of Ewing Sarcoma Defines an Aggressive Subtype with Co-Association of STAG2 and TP53 MutationsCancer Discovery, 2014
- Prognostic significance of high-risk human papillomavirus and p16(INK4A) in patients with esophageal squamous cell carcinoma.2014
- CDKN2A(p16) and HRAS are frequently mutated in vulvar squamous cell carcinomaGynecologic Oncology, 2014
- Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortalScience Signaling, 2013
- Molecular predictors of locoregional and distant metastases in oropharyngeal squamous cell carcinomaJournal of Otolaryngology - Head & Neck Surgery, 2013
- Prognostic value of aberrant hypermethylation in pleural effusion of lung adenocarcinomaCancer Biology & Therapy, 2012
- Hypermethylation of p16 gene promoter correlates with loss of p16 expression that results in poorer prognosis in esophageal squamous cell carcinomasDiseases of the Esophagus, 2008
- DAVID Bioinformatics Resources: expanded annotation database and novel algorithms to better extract biology from large gene listsNucleic Acids Research, 2007
- ONCOMINE: A Cancer Microarray Database and Integrated Data-Mining PlatformNeoplasia, 2004